The major difference between these two platforms is that in the anti-tumor approach, we use tumor cells as a source of antigens by transfecting gp96-Ig construct in individual tumor cell lines, while in the anti-infectious approach, we have chosen the ATCC human embryonal kidney (HEK)-293 cell line, as a vehicle for gp96-Ig delivery in combination with different antigenic peptides that are co-transfected in the cell where the final product is gp96-Ig complexed with array of different antigenic peptides [37] (Figure 1C). This evidence concerns the gene HSP90B1 and neoplasm.